This course aims to provide healthcare professionals with comprehensive knowledge and skills for managing immune-related toxicities in patients with squamous non-small cell lung cancer (NSCLC).

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this activity, the participants should be able to: 

• Recognize the currently approved immune checkpoint inhibitors (ICIs)-based regimens in advanced NSCLC.
• Implement effective techniques for identifying and managing immune-related adverse events (irAEs) in patients during ICI treatment and after its discontinuation.
• Consider complex cases in a multidisciplinary manner, namely with colleagues from other specialties.
• Manage the side effects of the immune-suppressive drugs given to treat irAEs.

• Mariana Brandao, MD, PhD, Associate Professor, Université Libre de Bruxelles, Brussels, Belgium

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.